Asynchronous replication of AURKA and TP53 genes in gastric cancer patients and patients with multiple tumors

Background. The correct genome replication is essential for normal cell division to guarantee that genetic information comes changeless through the next cells generations. DNA replication is a strictly regulated and synchronous process and its disturbances could result to mutations appearances. Aberrant time of DNA replication affects on gene expression causes changes of epigenetic modifications and influences on increasing the structural rearrangements leading to enhanced genome disbalance. Replication time failure as asynchronous replication is common for cancerogeneses.

The objective of our study was the assessment of asynchronous replication levels in patients with gastric cancer and patients with multiple tumors.

Materials and methods. Fluorescence in situ hybridization (FISH) was used for the asynchronous replication of AURKA and TP53 genes analyses. Interphase FISH on lymphocytes of peripheral blood of 37 healthy donors, 19 patients with non-cancer gastrointestinal pathologies, 68 patients with solitary gastric cancer and 39 patients with multiple tumors having gastric cancer and other second synchronous or metachronous tumor was carried out.

Results. Values of lymphocytes with asynchronous replication for AURKA were 19.8 ± 0.5 % for control group, 24.7 ± 0.4 % for non-cancer patients, 32.5 ± 0.5 % for gastric cancer patients, 39.5 ± 0.6 % for patients with multiple tumors and 17.3 ± 0.5, 19.5 ± 0.7, 26.1 ± 0.7 and 32.5 ± 0.6 % for TP53 respectively. Differences between cell populations of examined groups had statistical significance with p <0.01 for both studied gene. Also there was statistical difference between gastric cancer patients having distant metastases and gastric cancer patients without metastases for AURKA (34.4 ± 1.0 % vs. 31.7 ± 0.6 %; p = 0.02).

Conclusion. High lymphocytes with asynchronous replication level in oncological patients could serve as potential marker of second tumor or possible metastatic process including the earliest stage of it. 

1. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011;144(5):646–74. DOI: 10.1016/j.cell.2011.02.013.

2. Blumenfeld B., Ben-Zimra M., Simon I. Perturbations in the replication program contribute to genomic instability in cancer. Int J Mol Sci 2017;18(6):1138. DOI: 10.3390/ijms18061138.

3. Donley N., Thayer M.J. DNA replication timing, genome stability and cancer: late and/or delayed DNA replication timing is associated with increased genomic instability. Semin Cancer Biol 2013;23(2):80–9. DOI: 10.1016/j.semcancer.2013.01.001.

4. Farkash-Amar Sh., Itamar S. Genome-wide analysis of the replication program in mammals. Chromosome Res 2010;18:115–25. DOI: 10.1007/s10577-009-9091-5.

5. Ryba T., Battaglia D., Chang B.H. et al. Abnormal developmental control of replication-timing domains in pediatric acute lymphoblastic leukemia. Genome Res 2012;22(10):1833–44. DOI: 10.1101/gr.138511.112.

6. Mikhailova G.F., Tsepenko V.V., Shkavrova T.G., Goloub E.V. Asynchronous replication in oncological patients. Uspekhi molekulyarnoy onkologii = Advances in Molecular Oncology 2018;5(1):26–34. (In Russ.).

7. Malignant tumors in Russia in 2017 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMIRTS radiologii” Minzdrava Rossii, 2018. 250 p. (In Russ.).

8. Kim J.W., Jang J.Y., Chang Y.W., Kim Y.H. Clinical features of second primary cancers arising in early gastric cancer patients after endoscopic resection. World J Gastroenterol 2015;21(27):8358–65. DOI: 10.3748/wjg.v21.i27.8358.

9. Ławniczak M., Gawin A., JaroszewiczHeigelmann H. et al. Synchronous and metachronous neoplasms in gastric cancer patients: a 23-year study. World J Gastroenterol 2014;20(23):7480–7. DOI: 10.3748/wjg.v20.i23.7480.

10. Chirila N.D., Turdeanu N.A., Constantea N.A. et al. Multiple malignant tumors. Chirurgia 2013;108(4):498–502.

11. Katsha A., Belkhiri A., Goff L., El-Rifai W. Aurora kinase A in gastrointestinal cancers: time to target. Molecular Cancer 2015;14:106. DOI 10.1186/s12943-015-0375-4.

12. Almazov V.P., Kochetkov D.V., Chumakov P.M. The use of p53 as a tool for therapy of human cancer. Molekulyarnaya biologiya = Molecular Biology 2007;41(6):947–63. (In Russ.).

13. Zhu X., Mei J., Wang Zh. AuroraA kinase: potential tumor marker of osteosarcoma. J Can Res Ther 2014;10(2):102–7. DOI: 10.4103/0973-1482.145804.